Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Michael Charles Heinrich, Christopher L. Corless, George D. Demetri et al. · Journal of Clinical Oncology · 2003
PURPOSE: Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate. The relationship between mutations in these kinases and clinical response to imatinib was examined in a group of patients with advanced GIST. PATIENTS AND METHODS: GISTs from 127 patients enrolled onto a phase II clinical study of imatinib were examined for mutations of KIT or PDGFRA. Mutation types were correlated with clinical outcome. RESULTS: Activating mutations of KIT or PDGFRA were found in 112 (88.2%) and six (4.7%) GISTs, respectively. Most KIT mutations involved exon 9 (n = 23) or exon 11 (n = 85). All KIT mutant isoforms, but only a subset of PDGFRA mutant isoforms, were sensitive to imatinib, in vitro. In patients with GISTs harboring exon 11 KIT mutations, the partial response rate (PR) was 83.5%, whereas patients with tumors containing an exon 9 KIT mutation or no detectable mutation of KIT or PDGFRA had PR rates of 47.8% (P =.0006) and 0.0% (P <.0001), respectively. Patients whose tumors contained exon 11 KIT mutations had a longer event-free and overall survival than those whose tumors expressed either exon 9 KIT mutations or had no detectable kinase mutation. CONCLUSION: Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clinical response to imatinib. PDGFRA mutations can explain response and sensitivity to imatinib in some GISTs lacking KIT mutations.
Cited by 2,299 works. doi:10.1200/jco.2003.04.190
Authors
- Michael Charles Heinrich
- Christopher L. Corless
- George D. Demetri
- Charles David Blanke
- Margaret von Mehren
- Heikki Joensuu
- Laura S. McGreevey
- Chang-Jie Chen
- Annick D. Van den Abbeele
- Brian J. Druker
- Beate Kiese
- Burton Larry Eisenberg
- Peter Roberts
- Samuel Singer
- Christopher D.�M. Fletcher
- Sandra Silberman
- Saša Dimitrijević
- Jonathan Alfred Fletcher
References
- Nonparametric Estimation from Incomplete Observations
- Regression Models and Life-Tables
- Regression Models and Life-Tables
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification